Syndax Q2 net loss $68.1M, revumenib PDUFA extended to Dec 26, 2024

Syndax Pharmaceuticals Inc

2024-Q2 EPS reported -$1.65 revenue$3,500,000

Net loss of $68.1M ($0.80/sh) vs $44.6M ($0.64/sh) in Q2 2023; cash $454.6M as of June 30.
R&D expenses $48.7M, SG&A $29.1M; FY2024 opex guidance $355-375M with sufficient capital through 2026.
Revumenib NDA for R/R KMT2Ar leukemia PDUFA extended to Dec 26, 2024; AUGMENT-101 mNPM1 AML data expected 4Q24.
Axatilimab BLA for chronic GVHD under Priority Review with PDUFA date Aug 28, 2024.
Appointed Dr. Aleksandra Rizo to Board of Directors in May 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.